Indevus/Pliva Sanctura clears FDA
Executive Summary
Indevus/Pliva's Sanctura (trospium) clears FDA May 28 for treatment of overactive bladder. Product will be launched in third quarter. Sanctura is first new molecular entity approved for overactive bladder since Pharmacia's Detrol (tolterodine) in 1998 [Editor's Note: More coverage of the Sanctura approval appears in 1"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]....